Please login to the form below
aspirin
This page shows the latest aspirin news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca’s Brilinta reduces rate of secondary stroke
Detailed results from the phase 3 THALES trial also showed that Brilinta, given at a dose of 90mg twice-daily alongside aspirin, significantly reduced the rate of ischaemic stroke by 21%, ... The drug also reduced the risk for severe bleeding events –
Latest news
-
AZ says Brilinta hits the mark in new stroke trial
This time round, AZ evaluated Brilinta (ticagrelor) at a dose of 90-mg twice-daily, taken with aspirin for 30 days, in the phase 3 THALES trial. ... AZ has already tried to prove Brilinta’s benefit over aspirin in preventing stroke, but failed to do so
-
AZ unveils phase 3 Brilinta data in CAD and type 2 diabetes
The study demonstrated that Brilinta plus aspirin reduced the risk of cardiovascular death, heart attack or stroke by 10% compared to aspirin alone.
-
AZ says Brilinta hits the mark in diabetic heart disease
The study showed that in diabetics with CAD and no prior history of heart attack or stroke, Brilinta given on top of aspirin therapy achieved a statistically-significant reduction in a ... Last year, the GLOBAL LEADERS study last year also showed that
-
Xarelto no better than aspirin in secondary stroke study
low-dose aspirin, which is commonly prescribed for this purpose, but failed to hit the mark at the interim stage. ... While bleeding rates were low overall, an increase in bleeding was observed in the rivaroxaban arm compared to the low dose aspirin arm,
-
Xarelto beats aspirin for recurrent blood clots
A new phase III trial shows that Bayer and Janssen's novel oral anticoagulant (NOAC) Xarelto is more effective than aspirin at preventing recurrent blood clots, with no increase in bleeding ... It's already known that after an initial few months of
More from news
Approximately 1 fully matching, plus 71 partially matching documents found.
Latest Intelligence
-
Deal Watch September 2016
Zontivity is a protease-activated receptor-1 antagonist indicated for use in combination with daily aspirin and/or clopidogrel to reduce thrombotic cardiovascular events.
-
Using social data to see patients more clearly
Drugs and databases analysed. The study focused on two drugs, aspirin and Lipitor, that had a relatively high prevalence among the ADR reports in both the clinical and the social media ... To begin with, the two most common reactions to aspirin in both
-
Lonafarnib: promising results in first-ever trial for progeria
Low-dose aspirin is often used for prevention of heart attacks and children have received heart bypass surgery.
-
Country report: The healthcare market in Germany
Pharmaceutical market. With a tradition of invention in the medical field that brought aspirin, Germany has been an attractive pharmaceutical market for years.
-
Country report: The healthcare market in Japan
Under the revised Pharmaceutical Affairs Act, supermarkets and other stores can sell non-prescription drugs, including cold tablets and aspirin.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Natasha Giordano joins PLx Pharma
We are confident Natasha will be a driving force for PLx as we transition from the development phase to the commercial launch of our lead product, PL2200 Aspirin.”. ... I look forward to building on the compelling clinical data and initial market
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Introduction to the manufacturing of biologics
There is a significant distinction that needs to be made between traditional small molecule pharmaceuticals (such as aspirin), and biopharmaceuticals.
-
Are we harnessing the full emotional power of brand creativity?
In their 1981 experiment, psychologists Branthwaite and Cooper concluded that branded aspirin tablets were “significantly more effective than unbranded tablets in relieving headaches” accounting for some “one-quarter to one-third”
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Account Director
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
-
Medical Editor
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- Nucleus Global announces a trio of promotions
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Pfizer introduces new logo in a ‘shift from commerce to science’
- PHE study finds people who have had COVID-19 can still transmit the virus
- Pfizer, BioNTech temporarily slow down shipments of COVID-19 vaccine to EU
- CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
JPA Health
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
